|Articles|April 4, 2016
Therapeutic Innovation & Regulatory Science (TIRS): Focus on Pharmaceutical Compounding
Author(s)DIA
Advertisement
Pharmaceutical compounding is an essential aspect of medicine in the US, although with inherent risks that must be understood and managed. In May 2016, the Special Section of
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis
2
Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
3
GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate
4
FDA Expands Indication for Merck’s Winrevair in Pulmonary Arterial Hypertension
5
